We are live on ! Find out more
NHAS

Novo Holdings A/S Portfolio holdings

AUM $1.23B
1-Year Est. Return 81.32%
This Fund
S&P 500
This Quarter Est. Return
+25.44%
1 Year Est. Return
+81.32%
3 Year Est. Return
+192.63%
5 Year Est. Return
+125.03%
10 Year Est. Return
+943.65%
AUM
$1.62B
AUM Growth
+$266M
Cap. Flow
-$127M
Cap. Flow %
-7.84%
Top 10 Hldgs %
60.86%
Holding
43
New
3
Increased
6
Reduced
5
Closed
7

Top Buys

Rank Stock Value
1
VERV
Verve Therapeutics
VERV
+$24.8M
2
CRGX
CARGO Therapeutics
CRGX
+$21.2M
3
LXEO icon
Lexeo Therapeutics
LXEO
+$16.2M
4
FOLD
Amicus Therapeutics
FOLD
+$4.59M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$4.42M

Top Sells

Rank Stock Value
1
IRON icon
Disc Medicine
IRON
+$51.2M
2
ACLX
Arcellx
ACLX
+$38.6M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$33.9M
4
CORT icon
Corcept Therapeutics
CORT
+$26.5M
5
OKUR
OnKure Therapeutics
OKUR
+$25.3M

Sector Composition

Rank Sector Weight
1 Healthcare 52.2%
2 Technology 25.25%
3 Financials 11.17%
4 Industrials 4.91%
5 Communication Services 4.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CBAY
26
DELISTED
Cymabay Therapeutics
CBAY
$21.3M 1.31%
900,000
-666,521
-43% -$11.9M
SPRB
27
Spruce Biosciences
SPRB
$129M
$19.7M 1.22%
89,631
– –
LXEO icon
28
Lexeo Therapeutics
LXEO
$378M
$17.6M 1.08%
+1,307,829
New +$16.2M
INSP icon
29
Inspire Medical Systems
INSP
$1.74B
$13.3M 0.82%
65,524
+5,524
+9% +$895K
IOBT
30
DELISTED
IO Biotech
IOBT
$10.8M 0.67%
5,747,067
– –
ABCL icon
31
AbCellera Biologics
ABCL
$2.12B
$6.43M 0.4%
1,126,915
– –
TMCI icon
32
Treace Medical Concepts
TMCI
$309M
$4.59M 0.28%
360,000
– –
RLYB icon
33
Rallybio
RLYB
$85.8M
$4.23M 0.26%
220,983
-52,517
-19% -$1.28M
MQ icon
34
Marqeta
MQ
$1.66B
$3.08M 0.19%
110,390
– –
LVTX
35
DELISTED
LAVA Therapeutics
LVTX
$2.97M 0.18%
1,878,194
-521,806
-22% -$745K
DMRA
36
Damora Therapeutics, Inc. Ordinary Shares
DMRA
$1.84B
$1.8M 0.11%
99,912
– –
ACLX
37
DELISTED
Arcellx
ACLX
– –
-1,075,000
Closed -$38.6M
IRON icon
38
Disc Medicine
IRON
$2.97B
– –
-1,090,772
Closed -$51.2M
OKUR
39
OnKure Therapeutics
OKUR
$168M
– –
-333,038
Closed -$25.3M
SILK
40
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
– –
-333,884
Closed -$5M
KNTE
41
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
– –
-815,707
Closed -$1.14M
CYT
42
DELISTED
Cyteir Therapeutics, Inc. Common Stock
CYT
– –
-676,379
Closed -$1.92M
SGEN
43
DELISTED
Seagen Inc. Common Stock
SGEN
– –
-159,986
Closed -$33.9M
1
2

Similar funds

MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
HTHT
Hemenway Trust Hemenway Trust Salem, New Hampshire $1.24B AUM 16.52% 1-Year Est. Return
BCP
BlackBarn Capital Partners New York $1.24B AUM 55.98% 1-Year Est. Return
SPC
Stony Point Capital New York $1.24B AUM 32.69% 1-Year Est. Return
SC
Strategy Capital Los Altos, California $1.22B AUM 27.02% 1-Year Est. Return

Novo Holdings A/S's Q4 2023 Portfolio in Review

As of Q4 2023, Novo Holdings A/S held 43 positions worth $1.62B, up 20% from $1.35B the previous quarter. Its ten largest holdings account for 61% of the portfolio.

Novo Holdings A/S withdrew a net $127M in Q4 2023, closing 7 positions and reducing 5 holdings. Its most notable exit was Disc Medicine, an estimated $51.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 52% of assets, up from 51% a quarter earlier, followed by Technology and Financials.

Against the trend, Novo Holdings A/S opened a new position in Verve Therapeutics worth $27.9M.

  • Novo Holdings A/S's largest Q4 2023 buy was Verve Therapeutics: 2,000,000 shares worth $27.9M.
  • Novo Holdings A/S added most to Amicus Therapeutics in Q4 2023, an estimated $4.59M increase.
  • Novo Holdings A/S's biggest Q4 2023 reduction was Corcept Therapeutics, cutting an estimated $26.5M.
  • Novo Holdings A/S fully exited Disc Medicine in Q4 2023, selling an estimated $51.2M.
  • Novo Holdings A/S's ten largest holdings make up 61% of its $1.62B portfolio in Q4 2023.
  • Novo Holdings A/S opened 3 new positions and closed 7 in Q4 2023.
  • Novo Holdings A/S's portfolio value rose 20% quarter-over-quarter to $1.62B.

Based on Novo Holdings A/S's 13F filing for Q4 2023, filed 14 Feb 2024.